摘要
目的探讨白细胞介素6(IL-6)基因-572C/G多态性与中国人群缺血性脑卒中(IS)风险的相关性。方法计算机检索Pub Med、EMbase、CBM、CNKI和Wan Fang数据库,查找关于IL-6基因-572C/G多态性与中国人群IS发病风险相关性的病例-对照研究,检索时限均为建库至2015年12月。由2位评价员按照纳入与排除标准独立进行文献筛选、提取资料和方法学质量评价后,采用Stata 12.0软件进行Meta分析。结果最终纳入8个病例-对照研究,共包括1870例IS患者和1915例健康对照者。Meta分析结果显示,IL-6基因-572C/G多态性可能会增加中国人群IS发病风险(G vs.C:OR=1.38,95%CI:1.14~1.67;GC vs.CC:OR=1.50,95%CI:1.26~1.78;GG+GC vs.CC:OR=1.53,95%CI:1.26~1.85)。根据种族进行亚组分析结果显示,该风险在汉族人群中更为显著,但可能会降低维吾尔族人群IS发病风险。结论 IL-6基因-572C/G多态性可能会增加中国人群IS发病风险,尤其是汉族人群。鉴于纳入研究的数量限制,该结论尚需进一步验证。
Objective To discuss the correlation between polymorphism of interleukin-6(IL-6)gene-572C/G and risk of ischemic stroke(IS)in Chinese population.Methods The databases of PubMed,EMbase,CBM,CNKI and WanFang Database were retrieved with computer for searching the case-control studies on thecorrelation between polymorphism of IL-6gene-572C/G and risk of IS in Chinese population up to Dec.2015.Theliterature was screened and data was extracted by2researchers independently according to inclusion and exclusioncriteria,and after quality review on methodology the data was given a Meta-analysis by using Stata12.0software.Results There were totally8case-control studies including1870cases of IS patients and1915health controls.The results of Meta-analysis showed that polymorphism of IL-6gene-572C/G might increase the risk of IS inChinese population(G vs.C:OR=1.38,95%CI:1.14~1.67;GC vs.CC:OR=1.50,95%CI:1.26~1.78;GG+GC vs.CC:OR=1.53,95%CI:1.26~1.85).The results of analysis in subgroups grouped according to race showed that the riskof IS was more significant in Han population,and decreased in Uygur population.Conclusion The polymorphismof IL-6gene-572C/G can increase the risk of IS in Chinese population,especially in Han population.As thequantitative limitation of included studies,the conclusion is needed further verification.
作者
徐悦
翁鸿
范元腾
XU Yue;WENG Hong;FAN Yuan-teng(Department of Neurology, People's Hospital of Shiyan City, Hubei College of Medicine, Shiyan 442000, China)
出处
《中国循证心血管医学杂志》
2017年第2期145-148,共4页
Chinese Journal of Evidence-Based Cardiovascular Medicine